What We're Reading: Page 235
Industry reads hand-picked by our editors
Dec 03, 2018
Nov 30, 2018
-
Business Insider
Novartis CEO said he was 'completely blindsided' by Michael Cohen contract
-
Financial Times
Nimble biotechs become vital partners for large pharma groups
-
STAT
An FDA approval could come at a major cost for patients
-
The Wall Street Journal
Biotech looks ready for its deal test
Nov 29, 2018
Nov 28, 2018
-
Kaiser Health News
Chronically ill, traumatically billed: The $123,000 medicine for MS
-
Reuters
Medicine or vice? Socially screened funds struggle to define cannabis industry
-
The Wall Street Journal
Big tech expands footprint in health
Nov 27, 2018
Nov 26, 2018
-
Reuters
U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million
-
The New York Times
This City’s Overdose Deaths Have Plunged. Can Others Learn From It?
-
The Wall Street Journal
Pharma Stocks Soothe Stock-Market Malady
Nov 21, 2018
-
The New York Times
Will we ever cure Alzheimer's?
-
The Wall Street Journal
New ideas to fight the flu
-
Financial Times
Pharma companies put faith in AI for breakthroughs
-
The Washington Post
Everyone at high risk of HIV should be offered preventive meds, panel says
Previous
